Thierry M. Jahan

Thierry M. Jahan M.D.

Clinical Professor of Medicine; Bonnie J. and Anthony Addario Endowed Chair in Thoracic Oncology; Director of Clinical Services, Division of Hematology/Oncology

Specialty: Hematology/Oncology
Medical Treatment Center: The UCSF Helen Diller Family Comprehensive Cancer Center 1600 Divisadero Street, San Francisco, CA 94115

About Dr. Jahan

Thierry Jahan, M.D., is a clinical professor of medicine at the University of California, San Francisco Medical Center, where he is also director of clinical services for the UCSF Helen Diller Family Comprehensive Cancer Center’s division of hematology/oncology. Dr. Jahan’s practice is not limited to lung cancer patients, as he also treats patients with mesothelioma, sarcomas and endocrine tumors.

Dr. Jahan often recommends that his patients obtain several forms of treatment, known as a multimodal approach, which blends several treatments to give patients the best possible chance for recovery.

Another important focus of Dr. Jahan’s practice is palliative care. When patients are ineligible for potentially curative treatments like surgery, chemotherapy or radiation therapy, palliative treatments can help alleviate painful symptoms and improve quality of life. Dr. Jahan’s commitment to providing this comforting care earned him the Friend of the Palliative Care Service Award in 2006.

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get in contact with Dr. Jahan and find the treatment that's best for you.

Get Started Today Connect with a Top Mesothelioma Doctor

Multimodal Therapies

A significant amount of Dr. Jahan’s research explores multimodal therapies for lung cancer and mesothelioma. He has lectured nationally and internationally on these topics and contributed to numerous book chapters and journal articles, including a 2012 National Comprehensive Cancer Network overview of clinical practice guidelines in oncology for pleural mesothelioma.

Dr. Jahan has also served as primary investigator in several clinical trials, including a phase II clinical trial that evaluates the safety and effectiveness of the monoclonal antibody drug MM-121 in patients with non-small cell lung cancer. He also directed the research in a randomized phase II study that aims to determine the potential benefits of maintenance therapy with Alimta for pleural mesothelioma patients who have completed first-line chemotherapy.

A hands-on residency and fellowship at Cedars Sinai Medical Center in Los Angeles provided Dr. Jahan with the medical experience he now uses in his own practice. He initially joined the team at the University of California’s Division of Hematology and Oncology as a clinical fellow and worked his way up to his current positions.

Dr. Jahan is well known for the compassion he has for his patients. “When a person is told that he or she has cancer, they are stunned into silence,” said Bonnie J. and Anthony Addario, who named Dr. Jahan Endowed Chair in Thoracic Oncology for the Department of Surgery at University of California, San Francisco. “Thierry has a way of delivering that news with hope, compassion and a great sense of what the patient is feeling. He not only delivers world-class treatment, he also delivers hope.”


In 2002, Jahan published his only article discussing mesothelioma. The article, “Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma,” appeared in the Journal of Thoracic Cardiovascular Surgery.

Additional Resources

  1. UCSF Medical Center. (n.d.). Thierry Jahan, M.D. Retrieved from
  2. UCSF Helen Diller Comprehensive Cancer Center. (n.d.) Thierry M. Jahan, MD. Retrieved from
  3. UCSF Philanthropy Insider. (2009, November). Investiture Celebration for Renowned Thoracic Oncologist. Retrieved from
  4. UCSF Department of Surgery. (n.d.). A Study of MM-121 Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer. Retrieved from
  5. UCSF Department of Surgery. (n.d.). Pemetrexed Disodium or Observation in Treating Patients with Malignant Pleural Mesothelioma without Progressive Disease after First-Line Chemotherapy. Retrieved from

Share Our Page

View our resources for patients and families

Get Help Today
Click for Free Patient Resources